Health tech deal sourcing firms, ranked.
The health tech deal sourcing firms worth a shortlist in 2026 are easy to narrow for an unusual reason: health tech owners are the most willing to talk of any sector we have measured, yet not one of the six generalist firms we checked names health tech, digital health, or healthcare IT anywhere on its own live site. Across 10,245 emails to health tech owners in our owner response rates by sector research, 4.9 owners per 1,000 said yes to a conversation, the highest of twelve sectors measured and more than five times the all-sector average. We publish this list and DealSource Systems is our own service, so it is ranked first; the other six are ranked on fit, and our own healthcare sector coverage is what we run this vertical through. Every claim about the other six firms below is quoted from that firm's own live website, read in this run, and linked as the source.
A buyer with a health tech thesis is choosing between firms that treat the sector as one line in a 30-plus-industry buy box, and boutique investment banks built for health IT that run sell-side processes rather than the proactive buy-side outreach a deal sourcing firm runs. Neither option is wrong, but it helps to know which gap you are filling before signing a retainer.
Which health tech deal sourcing firms actually specialise in the sector
None of them, which is the headline finding here. Harvey & Company comes closest, naming "Healthcare Services" and "Medical Products" among 30-plus served sectors, but health tech, digital health, and healthcare IT appear nowhere on its site. The other five generalists do not name healthcare in any form, a wider gap than we found for the broader healthcare deal sourcing firms category, where the parent sector at least gets a mention.
Quick comparison
| Provider | Location | Best for | Starting price |
|---|---|---|---|
| DealSource Systems | Aarhus, Denmark (Danish Lead Co.), covers the US, UK and Europe | PE funds, M&A advisors and search funds building a health tech or digital health thesis | $4,000/month flat, published in full |
| Harvey & Company | Newport Beach, California | Enterprise-scale buy-and-build programmes across 30-plus generalist sectors | Contact for pricing |
| CAPTARGET | San Diego, California | Institutional buyers wanting broad market coverage, paid only on originated deals | Contact for pricing |
| SourceCo | Not published | Buyers wanting an AI-matched platform across a $2M to $200M revenue range | Contact for pricing |
| TruSight | Not published | Funds wanting a subscription feed of proprietary opportunities, sector-agnostic | Contact for pricing |
| Konverrt | Not published | Advisors and PE sponsors testing one vertical before committing to a retainer | A few thousand a month once qualified meetings land |
| CT Acquisitions | Sheridan, Wyoming | Founder-owned business sellers across 60-plus named verticals, success-fee model | Contact for pricing |
How we chose this list
We only considered firms that run owner outreach for buy-side mandates, not directories that hand over a list and leave the calling to the buyer. Every firm below states, on its own site, that it works buy-side origination for private equity, independent sponsors, family offices, or M&A advisors, and we checked each specifically for whether health tech, digital health, or healthcare IT appear as a named focus. None were current DealSource Systems clients or partners at the time of writing.
DealSource Systems
Best for: PE firms, M&A advisors, boutique investment banks and search funds who want owner conversations in a sector where the willingness is already there.
DealSource Systems is the origination arm of Danish Lead Co. AI maps the market and scores readiness signals, and an operator with deal experience reviews every message before an owner sees it, described on how it works. Pricing starts from $4,000 a month for a single thesis, no success fee, 90-day minimum. Our published proof point is a healthcare investment bank client that reached 14 owner conversations in three weeks and 133 within 90 days, and the data behind this post is broken out by healthcare sub-sector in healthcare sell-side mandates.
Harvey & Company
Best for: well-capitalised funds and corporations running buy-and-build strategies at enterprise scale, where sector depth across 30-plus generalist industries matters more than a health tech-specific record.
Harvey & Company is a buy-side acquisition search and advisory firm headquartered in Newport Beach, California. Its site lists Healthcare Services and Medical Products among 30-plus served sectors and serves "well-capitalized private equity funds and corporations." No health tech, digital health, or healthcare IT claim appears on harveyllc.com, and pricing is not published. DealSource Systems vs Harvey & Company sets that scale against our thesis-driven model.
CAPTARGET
Best for: funds and advisors wanting volume outreach plus broker-market monitoring, where health tech is one of many buy boxes rather than a stated focus.
CAPTARGET runs off-market owner outreach for a stated "Private equity, Corporate development, Family offices, Independent sponsors, Search funds, Buy-side advisors" client base, headquartered in San Diego, citing "1,500+ clients served since 2009" with "No Fees for Originated Deals." No health tech claim appears on captarget.com. DealSource Systems vs CAPTARGET weighs its success-fee model against our retainer, a trade-off also covered in deal origination pricing.
SourceCo
Best for: buyers who want a matching platform across a defined revenue band rather than a fully managed outreach programme.
SourceCo uses AI and proprietary data to match founder-led companies in the "$2 million to $200 million" range with private equity, corporate development, search fund and family office buyers, with sellers paying nothing. Named sectors on sourcecodeals.com lean industrial, automotive and B2B services; no health tech claim appears, and buyer pricing is not published. DealSource Systems vs SourceCo compares the matching model against an operator-run programme.
TruSight
Best for: funds and family offices wanting a steady subscription feed of proprietary opportunities without committing to a single sector thesis.
TruSight offers a "constant flow of targeted, proprietary acquisition opportunities," serving "professional investors, private equity funds, family office investors, and business intermediaries." No headquarters, no named sectors, and no health tech claim appear on trusightllc.com, and pricing is not published. DealSource Systems vs TruSight sets that sector-agnostic feed against a defined thesis.
Konverrt
Best for: an advisor or PE firm testing a health tech thesis before committing to a full retainer.
Konverrt runs a "deal origination engine" for lower middle market M&A advisors and PE firms targeting owner-operated businesses in the $1 million to $50 million range, with "no invoice until your first two qualified seller meetings" land. Named sectors on konverrt.com are manufacturing, construction, trades and B2B SaaS; no health tech claim or headquarters is published. DealSource Systems vs Konverrt is the closest read, since it sells the model nearest ours.
CT Acquisitions
Best for: opportunistic, success-fee searches against founder-owned sellers, where health tech sits outside its 60-plus named verticals today.
CT Acquisitions runs confidential, buyer-pays-at-close sourcing out of Sheridan, Wyoming, naming MSP and IT services among 60-plus served verticals, but not health tech, digital health, or healthcare IT specifically. Full pricing is not published beyond its success-fee structure on ctacquisitions.com. DealSource Systems vs CT Acquisitions weighs that model against a monthly retainer.
Why do health tech owners reply more than owners in other sectors
Because many health tech founders built their company expecting an exit, and many have investors who expect one too. Our healthcare sell-side mandates research splits healthcare into eight sub-sectors: health tech's 4.9 open owners per 1,000 emails sits well above physical therapy at 2.0 and far above medical practices at 0.2, a category roll-up buyers have targeted hard for years. Health tech also carried the lowest do-not-contact share in healthcare, 7% against a 19% healthcare average, consistent with a sector that has not been contacted to exhaustion.
That combination is also why specialist health IT investment banks exist, firms like HGP in Houston, TripleTree in Bloomington, Minnesota, and Edgemont Partners in New York: they run sell-side processes for health tech companies going to market, a different job from the buy-side outreach the firms above and DealSource Systems run. A buyer building a thesis needs the latter; an owner looking to sell usually hires the former.
How should a buyer choose between these health tech deal sourcing firms
- 1. Ask directly whether the firm has run a health tech mandate. None of the six named here state it on their own site, so a reference request separates a real track record from a buy box that happens to include it.
- 2. Decide whether you are buying or selling. The specialist health IT banks run sell-side processes; pick the category that matches your mandate, not just the sector name.
- 3. Price the volume against the sector's own response rate. At 4.9 open owners per 1,000 emails, twenty conversations needs roughly 4,000 to 5,000 emails, far less than a sector running at 0.5 or below. Our owner outreach calculator runs that math for any sector.
- 4. Separate reach from appetite, a distinction covered in our best industries for proprietary deal flow research.
Several of these providers also work outside this sector, and how the main deal sourcing companies compare covers them on fee model and process.
Conclusion
Health tech is the rare sector where the data argues for moving faster, not slower: owners reply more, decline less, and have mostly not been exhausted by other buyers yet. The providers available to run that outreach are generalists who do not name the sector, or specialist health IT banks built for the sell side rather than proactive buy-side origination, which is worth knowing before a retainer is signed. Our own corporate development deal sourcing and search fund roundups cover the same generalist pool against other buyer types, if health tech is one thesis among several on your list.
If you would rather have this run for you, DealSource Systems does off-market deal sourcing for lower middle market private equity: owners reached directly before they run a process, for a flat $4,000 a month.
Key Terms Glossary
Frequently asked questions
What is the best health tech deal sourcing firm for a first engagement?
It depends on whether the mandate is buy-side or sell-side. For buy-side proprietary outreach, DealSource Systems and the six generalists above are built for that job; for a company going to market, a specialist health IT bank like HGP or TripleTree runs that process.
Do any deal sourcing firms specialise only in health tech?
Not among the generalist deal sourcing firms we checked. Health tech sits inside a 30-plus sector buy box at Harvey & Company and is unnamed at the other five; sector-specific depth lives with investment banks built for health IT sell-side work instead.
Why are health tech owners more open to acquisition outreach than other sectors?
Our reading, based on 10,245 emails in this dataset, is that many health tech founders built their company with an exit in mind and have investors who expect one, and that the sector has been approached less than conventional healthcare roll-up categories like medical practices.
How many emails does a health tech buyer need to send for ten owner conversations?
At 4.9 open owners per 1,000 emails, roughly 2,000 emails produces ten open conversations, before list quality or deliverability. Our owner outreach calculator runs the exact math for a given target.
Is health tech outreach cheaper to run than other healthcare sub-sectors?
Not in list-building cost, but it is far more efficient per conversation. Our healthcare sell-side mandates data shows health tech needs about 205 emails per open owner against 5,618 for medical practices.
What does DealSource Systems charge for a health tech origination programme?
$4,000 a month for a single defined thesis, with a 90-day minimum and no success fee, published in full here.
Should a search fund consider health tech as a thesis?
It is worth evaluating alongside other options. Our deal sourcing firms for search funds roundup and search fund acquisition criteria guide cover how to weigh sector openness against deal economics and fund size.